{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:08:51Z","timestamp":1787238531347,"version":"build-2736575974"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>SARS-CoV-2 infection and COVID-19 vaccination can induce antibodies that cross-react with dengue virus (DENV). Pre-existing IgG antibodies against DENV are known to enhance infection through antibody-dependent enhancement (ADE) via Fc\u03b3 receptors. COVID-19 vaccines induce an altered IgG subclass distribution with modified Fc\u03b3 receptor affinity. This study investigates the isotype profile of DENV cross-reactive antibodies induced by COVID-19 vaccination and their potential to mediate ADE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively collected 271 serum samples from individuals in Taiwan who were either SARS-CoV-2-unvaccinated, vaccinated with 1\u20133 doses of COVID-19 vaccine, recipients of an Omicron-era booster, or previously recovered from dengue infection. Antibody titers (IgM, IgA, and IgG subclasses 1\u20134) against SARS-CoV-2 spike (S) glycoprotein and DENV serotype 2 envelope (E) protein were measured by enzyme-linked immunosorbent assay (ELISA). Selective depletion of anti-S or anti-E antibodies was performed to confirm cross-reactivity. ADE activity was assessed\n                      <jats:italic>in vitro<\/jats:italic>\n                      by incubating DENV-2 particles with serum antibodies followed by infection of Fc\u03b3 receptor-bearing THP-1 monocytic cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Cross-reactive anti-E antibodies in COVID-19-vaccinated individuals were predominantly IgM and IgA, whereas anti-S antibodies in vaccinated individuals and anti-E antibodies in dengue-recovered patients were dominated by IgG1. Low levels of cross-reactive anti-E IgG detected in vaccinated individuals were mainly of the low-affinity IgG2 and IgG4 subclasses. These vaccine-induced cross-reactive antibodies mediated significantly stronger\n                      <jats:italic>in vitro<\/jats:italic>\n                      ADE compared with antibodies from natural DENV infection, particularly after the first or second vaccine dose and after Omicron-variant boosters. Inactivation of complement reduced ADE in COVID-19-vaccinated sera but enhanced it in sera from dengue-recovered individuals.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>COVID-19 vaccination induces DENV cross-reactive antibodies with a distinct isotype profile and distinct ADE compared with natural dengue infection. Due to low Fc-affinity these antibodies likely do not pose a threat of dengue. These findings highlight the importance of considering off-target immunity and ADE risk in future vaccine design.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1683070","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:42:52Z","timestamp":1765953772000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["COVID-19 vaccination induces cross-reactive dengue virus antibodies with altered isotype profiles and in vitro antibody-dependent enhancement"],"prefix":"10.3389","volume":"16","author":[{"given":"Sebastian","family":"Reinig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuei-Ching","family":"Hsiung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ing-Kit","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Yen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Min","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Ru","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1139\/cjm-2020-0572","article-title":"Dengue virus: Epidemiology, biology, and disease aetiology","volume":"67","author":"Roy","year":"2021","journal-title":"Can J Microbiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e1011223","DOI":"10.1371\/journal.ppat.1011223","article-title":"Understanding antibody-dependent enhancement in dengue: Are afucosylated IgG1s a concern","volume":"19","author":"Teo","year":"2023","journal-title":"PloS Pathog"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-023-01421-y","article-title":"Human Fc\u03b3RIIIa activation on splenic macrophages drives dengue pathogenesis in mice","volume":"8","author":"Yamin","year":"2023","journal-title":"Nat Microbiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.975398","article-title":"Serological cross-reactivity among common flaviviruses","volume":"12","author":"Chan","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1207","article-title":"Potential antigenic cross-reactivity between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and dengue viruses","volume":"73","author":"Lustig","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.941923","article-title":"Antibodies against the SARS-CoV-2 S1-RBD cross-react with dengue virus and hinder dengue pathogenesis","volume":"13","author":"Cheng","year":"2022","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2020.12.037","article-title":"Computational modelling supports that dengue virus envelope antibodies can bind to SARS-CoV-2 receptor binding sites: Is pre-exposure to dengue virus protective against COVID-19 severity","volume":"19","author":"Nath","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25158180","article-title":"Enhanced assessment of cross-reactive antigenic determinants within the spike protein","volume":"25","author":"Lechuga","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e29793","DOI":"10.1002\/jmv.29793","article-title":"Specific long-term changes in anti-SARS-CoV-2 IgG modifications and antibody functions in mRNA, adenovector, and protein subunit vaccines","volume":"96","author":"Reinig","year":"2024","journal-title":"J Med Virol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ade2798","article-title":"Class switch towards non-inflammatory IgG isotypes after repeated SARS-CoV-2 mRNA vaccination","volume":"8","author":"Irrgang","year":"2023","journal-title":"Sci Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106317","article-title":"Mechanisms and implications of IgG4 responses to SARS-CoV-2 and other repeatedly administered vaccines","volume":"89","author":"Marchese","year":"2024","journal-title":"J Infect"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2007.09.015","article-title":"Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner","volume":"2","author":"Mehlhop","year":"2007","journal-title":"Cell Host Microbe"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.aai8128","article-title":"IgG antibodies to dengue enhanced for Fc\u03b3RIIIA binding determine disease severity","volume":"355","author":"Wang","year":"2017","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adx7231","article-title":"Afucosylation of anti-dengue IgG is associated with enhanced susceptibility to dengue virus infection postvaccination","volume":"17","author":"Ashraf","year":"2025","journal-title":"Sci Transl Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc7303","article-title":"Antibody fucosylation predicts disease severity in secondary dengue infection","volume":"372","author":"Bournazos","year":"2021","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1038\/s41467-023-38453-1","article-title":"Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody","volume":"14","author":"Gupta","year":"2023","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","first-page":"112630","DOI":"10.1016\/j.jim.2019.07.002","article-title":"A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation","volume":"473","author":"Fischinger","year":"2019","journal-title":"J Immunol Methods"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00992-07","article-title":"Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels","volume":"82","author":"Yamanaka","year":"2008","journal-title":"J Virol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2300307","article-title":"The influence of human IgG subclass and allotype on complement activation","volume":"211","author":"Damelang","year":"2023","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11121749","article-title":"Mapping IgA epitope and cross-reactivity between severe acute respiratory syndrome-associated coronavirus 2 and DENV","volume":"11","author":"De-Simone","year":"2023","journal-title":"Vaccines"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9071(200010)62:2<224::AID-JMV14>3.0.CO;2-C","article-title":"Dengue NS1-specific antibody responses: Isotype distribution and serotyping in patients with dengue fever and dengue hemorrhagic fever","volume":"62","author":"Shu","year":"2000","journal-title":"J Med Virol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0040021","DOI":"10.1128\/JCM.00400-21","article-title":"The specificity of the persistent IgM neutralizing antibody response in Zika virus infections among individuals with prior dengue virus exposure","volume":"59","author":"Calvert","year":"2021","journal-title":"J Clin Microbiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e70255","DOI":"10.1002\/jmv.70255","article-title":"Differential serotype specificity in the IgG subclass profile of the anti-domain III response elicited by dengue virus infection","volume":"97","author":"Gabriel","year":"2025","journal-title":"J Med Virol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/antib9020025","article-title":"Human natural antibodies to mammalian carbohydrate antigens as unsung heroes protecting against past, present, and future viral infections","volume":"9","author":"Galili","year":"2020","journal-title":"Antibodies"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e29430","DOI":"10.1371\/journal.pone.0029430","article-title":"Dengue virus activates polyreactive, natural IgG B cells after primary and secondary infection","volume":"6","author":"Balakrishnan","year":"2011","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0011421","DOI":"10.1371\/journal.pntd.0011421","article-title":"Epidemiology and risk factors of Japanese encephalitis in Taiwan, 2010\u20132022","volume":"17","author":"Hsu","year":"2023","journal-title":"PloS Negl Trop Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1186\/s12879-016-1873-8","article-title":"Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults","volume":"16","author":"Saito","year":"2016","journal-title":"BMC Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ads9572","article-title":"Dengue disease severity in humans is augmented by waning Japanese encephalitis virus immunity","volume":"17","author":"Malhotra","year":"2025","journal-title":"Sci Transl Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e1311","DOI":"10.1371\/journal.pntd.0001311","article-title":"Preexisting Japanese encephalitis virus neutralizing antibodies and increased symptomatic dengue illness in a school-based cohort in Thailand","volume":"5","author":"Anderson","year":"2011","journal-title":"PloS Negl Trop Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1020844","article-title":"mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine","volume":"13","author":"Buhre","year":"2023","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"13166","DOI":"10.1038\/s41598-023-40103-x","article-title":"Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history","volume":"13","author":"Kiszel","year":"2023","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.4.2132","article-title":"Variable-region-identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype","volume":"174","author":"Torres","year":"2005","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1200024109","article-title":"Antiviral activities of the anti-HIV-1 human broadly neutralizing 2F5 antibody","volume":"109","author":"Tudor","year":"2012","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B34","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.autrev.2015.04.004","article-title":"Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference","volume":"14","author":"Bonanni","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1016\/j.jaci.2021.10.026","article-title":"Isotype-specific binding patterns of serum antibodies to multiple conformational epitopes of Bet v 1","volume":"149","author":"Schmalz","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/antib5010002","article-title":"Autoantibodies in SLE: Specificities, isotypes and receptors","volume":"5","author":"Dema","year":"2016","journal-title":"Antibodies"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/antib6010005","article-title":"Epitope specificity of anti-citrullinated protein antibodies","volume":"6","author":"Trier","year":"2017","journal-title":"Antibodies"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2180-13-194","article-title":"Identification of a novel infection-enhancing epitope on dengue prM using a dengue cross-reacting monoclonal antibody","volume":"13","author":"Luo","year":"2013","journal-title":"BMC Microbiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.001852","article-title":"Dengue virus (DV) non-cross-reactive Omicron wave COVID-19 serums enhanced DV3 infectivity in vitro","volume":"73","author":"Sarker","year":"2024","journal-title":"J Med Microbiol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1683070\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:42:55Z","timestamp":1765953775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1683070\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2025.1683070"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1683070","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"article-number":"1683070"}}